FOLH1 and prostate carcinoma: Based upon PSMA overexpression on prostate cancer cells, radiopharmaceuticals targeting this transmembrane protein became a consolidated compound to improve the performances of molecular imaging and to develop new therapeutic instruments through radioligand therapy (RLT) in metastatic castration-resistant prostate cancer [20,21].